Avanos Medical Clears Regulatory Hurdle for AIP Acquisition

The path forward now centers on a special meeting of Avanos stockholders scheduled for July 22, 2026, in Atlanta. This vote serves as the final procedural requirement before the deal can formally close, assuming all other customary conditions are met or waived. David C. Pacitti, CEO of Avanos, described the regulatory clearance as a milestone that allows the company to focus on its next phase of commercial growth and medical innovation.

American Industrial Partners, an investment firm managing approximately $17.8 billion in assets, aims to leverage its industrial expertise to bolster Avanos's portfolio. Joel Rotroff, a partner at AIP, noted that the firm intends to support the company’s existing leadership to refine its medical device solutions and market execution. Avanos, known for its focus on pain management and nutrition support technology, has filed a definitive proxy statement with the SEC to provide investors with full transparency regarding the terms of the transaction.